1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Download response Cancer treatment. 181019